Pasithea stock is trading higher on a strong volume of 9.01 million versus an average of 17.3k as per data from Benzinga Pro.

Pharmacokinetics (PK)

• Plasma exposure increased with an increase in dose, and linear PK was observed.
• A long half-life of approximately 70 hours will allow for once-daily dosing or longer intervals.
• Prolonged systemic exposure with minimal fluctuation in PAS-004 plasma concentration at a steady state indicates a potential to achieve constant target inhibition.

Also Read: Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today – Here’s Why

Safety & Tolerability

• No treatment-related adverse events (TRAEs) or dose-limiting toxicities (DLTs) have been observed to date.
• In the first 2 dosing cohorts (n=6), PAS-004 was shown to be well-tolerated with a favorable safety profile with no drug-related dose interruptions, reductions or discontinuations.
• To date, no rash, skin toxicity, gastrointestinal (GI) toxicity, or ocular toxicity has been observed at the 2 and 4 mg dose levels.

The study’s independent Safety Review Committee has completed its safety review of data from the second dose cohort of 4 mg. The company has initiated cohort 3 dosing at an increased dose of 8 mg in capsules and filed a protocol amendment to increase the dosing schedule.

Price Action: At last check Thursday, KTTA stock was up 71.70% at $6.60 during the premarket session.

Read Next:

• Disney Trims Workforce By 300, Targets Corporate Departments for Cost Management.